We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Humana (HUM) Issues $1.25B Senior Notes, To Lower Debt Level
Read MoreHide Full Article
Humana Inc. (HUM - Free Report) recently concluded the issuance of senior notes with an aggregate principal amount of $1.25 billion. The notes were issued in two tranches with aggregate principal amounts of $500 million and $750 million, respectively. With interest rates of 5.750% and 5.875%, the two amounts are set to mature in 2028 and 2033, respectively.
Shares of Humana gained 1.4% on Nov 23.
Post subtracting underwriters’ discounts and anticipated offering expenses, HUM estimates to receive proceeds of around $1,232 million from the public offering of the senior notes.
Subsequently, Humana is expected to utilize the proceeds for paying back aggregate principal amounts of senior notes worth $600 million and $400 million, respectively. The two tranches of notes bear interest rates of 3.150% and 2.900%, respectively, and are scheduled to mature this year only.
After servicing the above-mentioned debts, the remaining amount can be utilized by Humana for addressing general corporate purposes that may comprise the repayment of borrowings as part of its commercial paper program. The program had an outstanding amount of $303 million as of Sep 30, 2022.
The latest move highlights Humana’s sincere efforts to reduce its mounting debt burden and associated interest expenses. As of Sep 30, 2022, HUM’s short-term debt (including the above-mentioned $303 million commercial paper borrowings) escalated 43.3% from the 2021-end level. Consequently, interest expenses increased 24.7% in the first nine months of 2022 from the same-period level in 2021. Rising interest expenses might stress Humana’s margins.
Sufficient cash reserves and a solid cash-generation ability can provide some respite to Humana from a heavy debt load. Cash and cash equivalents at the third-quarter end increased four-fold from the level at 2021 end. Also, net cash provided by operating activities increased more than four-fold in the first nine months of 2022 from the prior-year comparable period’s level.
HUM had resorted to a similar process of debt repayment in March 2022.
Despite a solid financial position, an increasing debt burden can limit a company’s capacity to meet its current obligations soon. Humana is no exception to this trend. Its times interest earned ratio of 10.3X at the third-quarter end was lower than the industry’s figure of 12.8X. Therefore, HUM must strive hard to service its debts continually, or else the creditworthiness of its stock could be dented.
Shares of Humana have gained 23.4% in a year compared with the industry’s rally of 16.3%.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Humana currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the Medical space are Medpace Holdings, Inc. (MEDP - Free Report) , Merit Medical Systems, Inc. (MMSI - Free Report) and United Therapeutics Corporation (UTHR - Free Report) . While Medpace currently flaunts a Zacks Rank #1 (Strong Buy), Merit Medical Systems and United Therapeutics carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The bottom line of Medpace surpassed estimates in each of the last four quarters, the average beat being 22.04%. The Zacks Consensus Estimate for MEDP’s 2022 earnings suggests an improvement of 44.9%, while the same for revenues indicates growth of 27.1% from the respective year-ago reported figures. The consensus mark for MEDP’s 2022 earnings has moved 13.1% north in the past 30 days.
Merit Medical Systems’ earnings outpaced estimates in each of the trailing four quarters, the average surprise being 25.35%. The Zacks Consensus Estimate for MMSI’s 2022 earnings suggests an improvement of 8.4% from the year-ago reported figure. The same for revenues suggests growth of 6.8% from the prior-year tally. The consensus mark for MMSI’s 2022 earnings has moved 4% north in the past 30 days.
The bottom line of United Therapeutics outpaced estimates in two of the last four quarters and missed the mark twice, the average being 7.24%. The Zacks Consensus Estimate for UTHR’s 2022 earnings suggests an improvement of 64.9% from the year-ago reported figure. The same for revenues suggests growth of 14.9% from the year-ago tally. The consensus mark for UTHR’s 2022 earnings has moved 12.8% north in the past 30 days.
Shares of Medpace, Merit Medical Systems and United Therapeutics have gained 2.1%, 4.3% and 33.3%, respectively, in a year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Humana (HUM) Issues $1.25B Senior Notes, To Lower Debt Level
Humana Inc. (HUM - Free Report) recently concluded the issuance of senior notes with an aggregate principal amount of $1.25 billion. The notes were issued in two tranches with aggregate principal amounts of $500 million and $750 million, respectively. With interest rates of 5.750% and 5.875%, the two amounts are set to mature in 2028 and 2033, respectively.
Shares of Humana gained 1.4% on Nov 23.
Post subtracting underwriters’ discounts and anticipated offering expenses, HUM estimates to receive proceeds of around $1,232 million from the public offering of the senior notes.
Subsequently, Humana is expected to utilize the proceeds for paying back aggregate principal amounts of senior notes worth $600 million and $400 million, respectively. The two tranches of notes bear interest rates of 3.150% and 2.900%, respectively, and are scheduled to mature this year only.
After servicing the above-mentioned debts, the remaining amount can be utilized by Humana for addressing general corporate purposes that may comprise the repayment of borrowings as part of its commercial paper program. The program had an outstanding amount of $303 million as of Sep 30, 2022.
The latest move highlights Humana’s sincere efforts to reduce its mounting debt burden and associated interest expenses. As of Sep 30, 2022, HUM’s short-term debt (including the above-mentioned $303 million commercial paper borrowings) escalated 43.3% from the 2021-end level. Consequently, interest expenses increased 24.7% in the first nine months of 2022 from the same-period level in 2021. Rising interest expenses might stress Humana’s margins.
Sufficient cash reserves and a solid cash-generation ability can provide some respite to Humana from a heavy debt load. Cash and cash equivalents at the third-quarter end increased four-fold from the level at 2021 end. Also, net cash provided by operating activities increased more than four-fold in the first nine months of 2022 from the prior-year comparable period’s level.
HUM had resorted to a similar process of debt repayment in March 2022.
Despite a solid financial position, an increasing debt burden can limit a company’s capacity to meet its current obligations soon. Humana is no exception to this trend. Its times interest earned ratio of 10.3X at the third-quarter end was lower than the industry’s figure of 12.8X. Therefore, HUM must strive hard to service its debts continually, or else the creditworthiness of its stock could be dented.
Shares of Humana have gained 23.4% in a year compared with the industry’s rally of 16.3%.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Humana currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the Medical space are Medpace Holdings, Inc. (MEDP - Free Report) , Merit Medical Systems, Inc. (MMSI - Free Report) and United Therapeutics Corporation (UTHR - Free Report) . While Medpace currently flaunts a Zacks Rank #1 (Strong Buy), Merit Medical Systems and United Therapeutics carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The bottom line of Medpace surpassed estimates in each of the last four quarters, the average beat being 22.04%. The Zacks Consensus Estimate for MEDP’s 2022 earnings suggests an improvement of 44.9%, while the same for revenues indicates growth of 27.1% from the respective year-ago reported figures. The consensus mark for MEDP’s 2022 earnings has moved 13.1% north in the past 30 days.
Merit Medical Systems’ earnings outpaced estimates in each of the trailing four quarters, the average surprise being 25.35%. The Zacks Consensus Estimate for MMSI’s 2022 earnings suggests an improvement of 8.4% from the year-ago reported figure. The same for revenues suggests growth of 6.8% from the prior-year tally. The consensus mark for MMSI’s 2022 earnings has moved 4% north in the past 30 days.
The bottom line of United Therapeutics outpaced estimates in two of the last four quarters and missed the mark twice, the average being 7.24%. The Zacks Consensus Estimate for UTHR’s 2022 earnings suggests an improvement of 64.9% from the year-ago reported figure. The same for revenues suggests growth of 14.9% from the year-ago tally. The consensus mark for UTHR’s 2022 earnings has moved 12.8% north in the past 30 days.
Shares of Medpace, Merit Medical Systems and United Therapeutics have gained 2.1%, 4.3% and 33.3%, respectively, in a year.